Ami Organics Limited IPO

Incorporated in 2004, Ami Organics Limited is one of the leading research and development driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical ingredients (API) for New Chemical Entities, and material for agrochemicals and fine chemicals.
The company has developed over 450 pharma intermediates across 17 key therapeutic areas i.e. anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant, and anti-coagulant. It supplies its products to more than 150 customers (including international customers) directly in India and in 25 countries overseas i.e. Europe, USA, China, Israel, Japan, Latin America, etc. Laurus Labs, Cadila Healthcare, Cipla Ltd are some of the domestic customers whereas Organike s.r.l.a. Socio Unico, Fermion Oly, Medichem S.A. and Midas Pharma GmbH are some of the international customers.
The company has three manufacturing facilities in Gujarat situated at Sachin, Ankleshwar & Jhagadia, with an aggregate installed capacity of 6,060 MTPA.

Competitive strengths:

  • One of the leading manufacturers of certain Pharma Intermediates i.e. Dolutegravir, Trazodone, Entacapone, Nintedanib and Rivaroxaban.
  • Strong and diversified product portfolio with 450+ Pharma Intermediates across 17 therapeutic areas.
  • Extensive geographical presence and diversified customer base.
  • Strong R&D, sales and marketing capabilities
  • Consistent financial performance track record.

Company Promoters:

  • Nareshkumar Ramjibhai Patel, Chetankumar Chhaganlal Vaghasia, Shital Nareshbhai Patel and Parul Chetankumar Vaghasia are the company promoters

Company Financials

Particulars For the year/period ended (₹ in million)
Summary of financial Information (Restated Consolidated) 31-Mar-21 31-Mar-20 31-Mar-19
Total Assets 4,132.68 2,318.92 2,131.52
Total Revenue 3,419.88 2,424.86 2,388.96
Profit After Tax 539.99 274.7 232.95

Objects of the Issue:

  • Repayment/prepayment of certain financial facilities availed by our Company.
  • Funding working capital requirements of our Company.
  • General corporate purposes.
(Read detailed report)

Issue Details


ISSUE OPENS
Wednesday, September 01, 2021

ISSUE CLOSES
Friday, September 03, 2021

ISSUE PRICE
Rs 603 - Rs 610 Per Equity Share.

BID LOT
24 Equity shares & multiple of 24 Equity shares thereafter.

IPO SIZE
Rs. 569.64 Cr

LISTING EXCHANGES
NSE & BSE

ALLOTMENT DATE
Tentatively Thursday, September 09, 2021

RATIOS
QIB 50% - Retail 35% - NIB 15%

Apply Now

You can Invest via:

  201404210316526522603845   201404210316526522603171   201404210316526522603762   201606080432378699589304.jpg

Open Account Now